Diagnosis of Cystic Fibrosis in Screened Populations

Journal of Pediatrics

Volumn 181, Issue , 2017, Pages S33-S44.e2

  Farrell, Philip M ^a   White, Terry B ^b   Howenstine, Michelle S ^c   Munck, Anne ^d   Parad, Richard B ^e   Rosenfeld, Margaret ^f   Sommerburg, Olaf ^g   Accurso, Frank J ^h   Davies, Jane C ⁱ   Rock, Michael J ^a   Sanders, Don B ^c   Wilschanski, Michael ^j   Sermet Gaudelus, Isabelle ^k   Blau, Hannah ^l   Gartner, Silvia ^m   McColley, Susanna A ⁿ  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CYSTIC FIBROSIS FOUNDATION   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g Heidelberg Cystic Fibrosis Centre   (Germany)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l TEL AVIV UNIVERSITY   (Israel)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

CF screen positive, inconclusive diagnosis; CFTR related metabolic syndrome; immunoreactive trypsinogen; intestinal current measurement; nasal potential difference; newborn screening; pancreatitis associated protein; sweat test

Indexed keywords

ELASTASE; TRYPSINOGEN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

AGE DISTRIBUTION; ARTICLE; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; CYSTIC FIBROSIS; MUTATION; NEWBORN SCREENING; PRIORITY JOURNAL; RESPIRATORY FUNCTION; STANDARDIZATION; GENETIC SCREENING; GENETICS; HUMAN; NEWBORN; PRACTICE GUIDELINE;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC TESTING; HUMANS; INFANT, NEWBORN; MUTATION; NEONATAL SCREENING; PRACTICE GUIDELINES AS TOPIC;

EID: 85010289609     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2016.09.065     Document Type: Article

References (103)

1. 1 Kosorok, M.R., Wei, W.H., Farrell, P.M., The incidence of cystic fibrosis. Stat Med 15 (1996), 449–462.
2. 2 Palomaki, G.E., FitzSimmons, S.C., Haddow, J.E., Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med 6 (2004), 405–414.
3. 3 Hamosh, A., FitzSimmons, S.C., Macek, M., Knowles, M.R., Rosenstein, B.J., Cutting, G.R., Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 132 (1998), 255–259.
4. 4 Kerem, B., Rommens, J.M., Buchanan, J.A., Markiewicz, D., Cox, T.K., Chakravarti, A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989), 1073–1080.
5. 5 Dorfman, R., for the CFMD/CFTR1 Team. Cystic Fibrosis mutation database [Internet]. http://www.genet.sickkids.on.ca/cftr/app Updated April 2011; Accessed May 3, 2016.
6. 6 CFTR2@Johns Hopkins—home page [Internet]. http://cftr2.org/ Updated August 2016; Accessed October 21, 2016.
7. 7 Grosse, S.D., Boyle, C.A., Botkin, J.R., Comeau, A.M., Kharrazi, M., Rosenfeld, M., et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53:RR–13 (2004), 1–36.
8. 8 Campbell, P.W. 3rd, White, T.B., Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. J Pediatr 147:Suppl 3 (2005), S2–5.
9. 9 Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153 (2008), S4–14.
10. 10 De Boeck, K., Wilschanski, M., Castellani, C., Taylor, C., Cuppens, H., Dodge, J., et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61 (2006), 627–635.
11. 11 Ren, C.L., Fink, A.K., Petren, K., Borowitz, D.S., McColley, S.A., Sanders, D.B., et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics 135 (2015), e1386–92.
12. 12 Parad, R.B., Comeau, A.M., Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr 147:Suppl 3 (2005), S78–82.
13. 13 Kharrazi, M., Yang, J., Bishop, T., Lessing, S., Young, S., Graham, S., et al. Newborn screening for cystic fibrosis in California. Pediatrics 136 (2015), 1062–1072.
14. 14 Levy, H., Farrell, P.M., New challenges in the diagnosis and management of cystic fibrosis. J Pediatr 166 (2015), 1337–1341.
15. 15 Tluczek, A., Chevalier McKechnie, A., Lynam, P.A., When the cystic fibrosis label does not fit: a modified uncertainty theory. Qual Health Res 20 (2010), 209–223.
16. 16 Tluczek, A., Orland, K.M., Cavanagh, L., Psychosocial consequences of false-positive newborn screens for cystic fibrosis. Qual Health Res 21 (2011), 174–186.
17. 17 Nelson, M.R., Adamski, C.R., Tluczek, A., Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens. J Cyst Fibros 10 (2011), 460–465.
18. 18 Munck, A., Mayell, S.J., Winters, V., Shawcross, A., Derichs, N., Parad, R., et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 14 (2015), 706–713.
19. 19 Cystic Fibrosis Foundation, Borowitz, D., Parad, R.B., Sharp, J.K., Sabadosa, K.A., Robinson, K.A., et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155:Suppl 6 (2009), S106–16.
20. 20 Ooi, C.Y., Dupuis, A., Ellis, L., Jarvi, K., Martin, S., Gonska, T., et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?. Thorax 67 (2012), 618–624.
21. 21 Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Patient Registry 2014 annual data report. 2015, Cystic Fibrosis Foundation, Bethesda (MD).
22. 22 Elborn, J.S., Cystic fibrosis. Lancet, 2016, 10.1016/S0140-6736(16)00576-6.
23. 23 Elborn, J.S., Bell, S.C., Madge, S.L., Burgel, P.-R., Castellani, C., Conway, S., et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 47 (2016), 420–428.
24. 24 Cystic Fibrosis Canada, The Canadian Cystic Fibrosis Registry. 2014 annual report. [Internet]. https://cysticfibrosis.uberflip.com/i/705240-cystic-fibrosis-canada-registry Accessed October 22, 2016.
25. 25 Bell, S.C., De Boeck, K., Amaral, M.D., New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 145 (2015), 19–34.
26. 26 Farrell, P.M., Lai, H.J., Li, Z., Kosorok, M.R., Laxova, A., Green, C.G., et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr 147:Suppl 3 (2005), S30–6.
27. 27 Dijk, F.N., Fitzgerald, D.A., The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis. Paediatr Respir Rev 13 (2012), 220–225.
28. 28 Salinas, D., Azen, C., Young, S., Keens, T., Kharrazi, M., Parad, R., Phenotypes of California CF newborn screen-positive children with CFTR 5T allele by TG repeat length. Genet Test Mol Biomarkers 20 (2016), 496–503.
29. 29 Farrell, P.M., White, T.B., Ren, C.L., Hempstead, S.E., Accurso, F., Derichs, N., et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr 181S (2017), S4–15.
30. 30 Baker, M.W., Groose, M., Hoffman, G., Rock, M., Levy, H., Farrell, P.M., Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros 10 (2011), 278–281.
31. 31 Kloosterboer, M., Hoffman, G., Rock, M., Gershan, W., Laxova, A., Li, Z., et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 123 (2009), e338–46.
32. 32 Sanders, D.B., Lai, H.J., Rock, M.J., Farrell, P.M., Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. J Cyst Fibros 11 (2012), 150–153.
33. 33 Padoan, R., Genoni, S., Moretti, E., Seia, M., Giunta, A., Corbetta, C., Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. Acta Paediatr 91 (2002), 82–87.
34. 34 Sontag, M.K., Lee, R., Wright, D., Freedenberg, D., Sagel, S.D., Improving the sensitivity and positive predictive value in a cystic fibrosis newborn screening program using a repeat immunoreactive trypsinogen and genetic analysis. J Pediatr 175 (2016), 150–158.
35. 35 Rock, M.J., Mischler, E.H., Farrell, P.M., Bruns, W.T., Hassemer, D.J., Laessig, R.H., Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test. Pediatr Pulmonol 6 (1989), 42–48.
36. 36 Clinical and Laboratory Standards Institute, Newborn screening for cystic fibrosis; approved guideline. CLSI document NBS05-A. 2011, Clinical and Laboratory Standards Institute, Wayne (PA).
37. 37 Prach, L., Koepke, R., Kharrazi, M., Keiles, S., Salinas, D.B., Reyes, M.C., et al. Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. J Mol Diagn 15 (2013), 710–722.
38. 38 Kammesheidt, A., Kharrazi, M., Graham, S., Young, S., Pearl, M., Dunlop, C., et al. Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens–implications for newborn screening. Genet Med 8 (2006), 557–562.
39. 39 Hughes, E.E., Stevens, C.F., Saavedra-Matiz, C.A., Tavakoli, N.P., Krein, L.M., Parker, A., et al. Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Hum Mutat 37 (2016), 201–208.
40. 40 Sosnay, P.R., Salinas, D.B., White, T.B., Ren, C.L., Farrell, P.M., Raraigh, K.S., et al. Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses. J Pediatr 181S (2017), S27–32.
41. 41 Pique, L., Graham, S., Pearl, M., Kharrazi, M., Schrijver, I., Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients. Genet Med, 2016, 10.1038/gim.2016.48 Epub ahead of print.
42. 42 Kay, D.M., Langfelder-Schwind, E., DeCelie-Germana, J., Sharp, J.K., Maloney, B., Tavakoli, N.P., et al. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening. Pediatr Pulmonol 50 (2015), 771–780.
43. 43 Sontag, M.K., Wright, D., Beebe, J., Accurso, F.J., Sagel, S.D., A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. J Pediatr 155 (2009), 618–622.
44. 44 Comeau, A.M., Parad, R.B., Dorkin, H.L., Dovey, M., Gerstle, R., Haver, K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113 (2004), 1573–1581.
45. 45 Munck, A., Dhondt, J.-L., Sahler, C., Roussey, M., Implementation of the French nationwide cystic fibrosis newborn screening program. J Pediatr 153 (2008), 228–233 233.e1.
46. 46 UK National Screening Committee [Internet], https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/397726/Cystic_Fibrosis_Lab_Guide_February_2014_v1.0_12_.pdf, 2014 Published; February; Accessed July 8, 2016.
47. 47 Sommerburg, O., Hammermann, J., Lindner, M., Stahl, M., Muckenthaler, M., Kohlmueller, D., et al. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Pediatr Pulmonol 50 (2015), 655–664.
48. 48 Sommerburg, O., Krulisova, V., Hammermann, J., Lindner, M., Stahl, M., Muckenthaler, M., et al. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. J Cyst Fibros 13 (2014), 15–23.
49. 49 Torresani, T., Fingerhut, R., Rueegg, C.S., Gallati, S., Kuehni, C.E., Baumgartner, M.R., et al. Newborn screening for cystic fibrosis in Switzerland–consequences after analysis of a 4 months pilot study. J Cyst Fibros 12 (2013), 667–674.
50. 50 Krulišová, V., Balaščaková, M., Skalická, V., Piskáčková, T., Holubová, A., Paděrová, J., et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. Eur J Pediatr 171 (2012), 1223–1229.
51. 51 Vernooij-van Langen, A.M.M., Loeber, J.G., Elvers, B., Triepels, R.H., Gille, J.J.P., Van der Ploeg, C.P.B., et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 67 (2012), 289–295.
52. 52 Sarles, J., Giorgi, R., Berthézène, P., Munck, A., Cheillan, D., Dagorn, J.-C., et al. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros 13 (2014), 384–390.
53. 53 Pybus, S., Barben, J., Castellani, C., Dankert-Roelse, J., Gartner, S., Kashirskaya, N., et al. Updated survey of newborn screening for cystic fibrosis [Abstract]. J Cyst Fibros, 13(Suppl 2), 2014, S48.
54. 54 Farrell, P.M., Sommerburg, O., Toward quality improvement in cystic fibrosis newborn screening: progress and continuing challenges. J Cyst Fibros 15 (2016), 267–269.
55. 55 Seror, V., Cao, C., Roussey, M., Giorgi, R., PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study. J Med Screen 23 (2016), 62–69.
56. 56 Sarles, J., Berthézène, P., Le Louarn, C., Somma, C., Perini, J.-M., Catheline, M., et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 147 (2005), 302–305.
57. 57 Castellani, C., Southern, K.W., Brownlee, K., Dankert Roelse, J., Duff, A., Farrell, M., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 8 (2009), 153–173.
58. 58 Southern, K.W., Munck, A., Pollitt, R., Travert, G., Zanolla, L., Dankert-Roelse, J., et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6 (2007), 57–65.
59. 59 Rock, M.J., Levy, H., Zaleski, C., Farrell, P.M., Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. Pediatr Pulmonol 46 (2011), 1166–1174.
60. 60 Bergougnoux, A., Boureau-Wirth, A., Rouzier, C., Altieri, J.-P., Verneau, F., Larrieu, L., et al. A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants. J Cyst Fibros 15 (2016), 309–312.
61. 61 Munck, A., Houssin, E., Roussey, M., The importance of sweat testing for older siblings of patients with cystic fibrosis identified by newborn screening. J Pediatr 155 (2009), 928–930 e1.
62. 62 Smyth, A.R., Bell, S.C., Bojcin, S., Bryon, M., Duff, A., Flume, P., et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 13:Suppl 1 (2014), S23–42.
63. 63 Munck, A., Delmas, D., Audrézet, M.-P., Lemonnier, L., Cheillan, D., Roussey, M., The French CF newborn screening: optimization of the programme by a centralized tracking process [Abstract]. J Cyst Fibros, 15, 2016, S17.
64. 64 Rock, M., Farrell, P., Sweat testing after abnormal CF newborn screening: a single center 20 year experience [Abstract]. Pediatr Pulmonol, 50(Suppl 41), 2015, 381.
65. 65 Laguna, T.A., Lin, N., Wang, Q., Holme, B., McNamara, J., Regelmann, W.E., Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis. Pediatr Pulmonol 47 (2012), 736–742.
66. 66 Highsmith, W.E., Burch, L.H., Zhou, Z., Olsen, J.C., Boat, T.E., Spock, A., et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331 (1994), 974–980.
67. 67 Lebecque, P., Leal, T., De Boeck, C., Jaspers, M., Cuppens, H., Cassiman, J.-J., Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med 165 (2002), 757–761.
68. 68 Feldmann, D., Couderc, R., Audrezet, M.-P., Ferec, C., Bienvenu, T., Desgeorges, M., et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat, 22, 2003, 340.
69. 69 Duguépéroux, I., De Braekeleer, M., The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype. Eur Respir J 25 (2005), 468–473.
70. 70 Sosnay, P.R., Siklosi, K.R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45 (2013), 1160–1167.
71. 71 Kiesewetter, S., Macek, M., Davis, C., Curristin, S.M., Chu, C.S., Graham, C., et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 5 (1993), 274–278.
72. 72 Thauvin-Robinet, C., Munck, A., Huet, F., Génin, E., Bellis, G., Gautier, E., et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 46 (2009), 752–758.
73. 73 Groman, J.D., Hefferon, T.W., Casals, T., Bassas, L., Estivill, X., Des Georges, M., et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 74 (2004), 176–179.
74. 74 Ren, C.L., Borowitz, D.S., Gonska, T., Howenstine, M.S., Levy, H., Massie, J., et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis. J Pediatr 181S (2017), S45–51.
75. 75 Cordovado, S.K., Hendrix, M., Greene, C.N., Mochal, S., Earley, M.C., Farrell, P.M., et al. CFTR mutation analysis and haplotype associations in CF patients. Mol Genet Metab 105 (2012), 249–254.
76. 76 O'Sullivan, B.P., Baker, D., Leung, K.G., Reed, G., Baker, S.S., Borowitz, D., Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr 162 (2013), 808–812 e1.
77. 77 Barben, J., Rueegg, C.S., Jurca, M., Spalinger, J., Kuehni, C.E., Swiss Cystic Fibrosis Screening Group. Measurement of fecal elastase improves performance of newborn screening for cystic fibrosis. J Cyst Fibros 15 (2016), 313–317.
78. 78 Beharry, S., Ellis, L., Corey, M., Marcon, M., Durie, P., How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease?. J Pediatr 141 (2002), 84–90.
79. 79 Borowitz, D., Baker, S.S., Duffy, L., Baker, R.D., Fitzpatrick, L., Gyamfi, J., et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 145 (2004), 322–326.
80. 80 Lai, H., Farrell, P.M., FIRST Study Group. Variability of fecal elastase during infancy: potential impact on its utility as a secondary criterion for CF newborn screening program [Abstract]. Pediatr Pulmonol, 51(Suppl 45), 2016 In press.
81. 81 Ooi, C.Y., Castellani, C., Keenan, K., Avolio, J., Volpi, S., Boland, M., et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 135 (2015), e1377–85.
82. 82 Sermet-Gaudelus, I., Girodon, E., Roussel, D., Deneuville, E., Bui, S., Huet, F., et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Thorax 65 (2010), 539–544.
83. − channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 127 (2004), 1085–1095.
84. 84 De Jonge, H.R., Ballmann, M., Veeze, H., Bronsveld, I., Stanke, F., Tümmler, B., et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 3:Suppl 2 (2004), 159–163.
85. 85 Clancy, J.P., Szczesniak, R.D., Ashlock, M.A., Ernst, S.E., Fan, L., Hornick, D.B., et al. Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. PLoS ONE, 8, 2013 e73905.
86. 86 Derichs, N., Pinders-Kessler, L., Bronsveld, I., Scheinert, S., Rückes-Nilges, C., de Jonge, H., et al. Multicenter European standardization and reference values for intestinal current measurement in rectal biopsies. [Abstract]. Pediatr Pulmonol, 48(Suppl 36), 2013, 300.
87. 87 Derichs, N., Sanz, J., Von Kanel, T., Stolpe, C., Zapf, A., Tümmler, B., et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 65 (2010), 594–599.
88. − secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis. PLoS ONE, 7, 2012 e47708.
89. 89 Matecki, S., Kent, L., de Boeck, K., Le Bourgeois, M., Zielen, S., Braggion, C., et al. Is the raised volume rapid thoracic compression technique ready for use in clinical trials in infants with cystic fibrosis?. J Cyst Fibros 15 (2016), 10–20.
90. 90 Anagnostopoulou, P., Egger, B., Lurà, M., Usemann, J., Schmidt, A., Gorlanova, O., et al. Multiple breath washout analysis in infants: quality assessment and recommendations for improvement. Physiol Meas 37 (2016), L1–15.
91. 91 Lum, S., Gustafsson, P., Ljungberg, H., Hülskamp, G., Bush, A., Carr, S.B., et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 62 (2007), 341–347.
92. 92 Kieninger, E., Singer, F., Fuchs, O., Abbas, C., Frey, U., Regamey, N., et al. Long-term course of lung clearance index between infancy and school-age in cystic fibrosis subjects. J Cyst Fibros 10 (2011), 487–490.
93. 93 Sly, P.D., Gangell, C.L., Chen, L., Ware, R.S., Ranganathan, S., Mott, L.S., et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 368 (2013), 1963–1970.
94. 94 Thia, L.P., Calder, A., Stocks, J., Bush, A., Owens, C.M., Wallis, C., et al. Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age?. Thorax 69 (2014), 320–327.
95. 95 Oppenheimer, E.H., Esterly, J.R., Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 2 (1975), 241–278.
96. 96 Blau, H., Linnane, B., Carzino, R., Tannenbaum, E.-L., Skoric, B., Robinson, P.J., et al. Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children. J Cyst Fibros 13 (2014), 106–110.
97. 97 Marcus, M.S., Sondel, S.A., Farrell, P.M., Laxova, A., Carey, P.M., Langhough, R., et al. Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. Am J Clin Nutr 54 (1991), 578–585.
98. 98 Bronstein, M.N., Sokol, R.J., Abman, S.H., Chatfield, B.A., Hammond, K.B., Hambidge, K.M., et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 120:4 Pt 1 (1992), 533–540.
99. 99 Ballestero, Y., Hernandez, M.I., Rojo, P., Manzanares, J., Nebreda, V., Carbajosa, H., et al. Hyponatremic dehydration as a presentation of cystic fibrosis. Pediatr Emerg Care 22 (2006), 725–727.
100. 100 Cystic Fibrosis Foundation, Borowitz, D., Robinson, K.A., Rosenfeld, M., Davis, S.D., Sabadosa, K.A., et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 155:Suppl 6 (2009), S73–93.
101. 101 Castellani, C., Macek, M., Cassiman, J.-J., Duff, A., Massie, J., ten Kate, L.P., et al. Benchmarks for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 9 (2010), 165–178.
102. 102 Tluczek, A., Zaleski, C., Stachiw-Hietpas, D., Modaff, P., Adamski, C.R., Nelson, M.R., et al. A tailored approach to family-centered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. J Genet Couns 20 (2011), 115–128.
103. 103 Knapp, E.A., Fink, A.K., Goss, C.H., Sewall, A., Ostrenga, J., Dowd, C., et al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry. Ann Am Thorac Soc 13 (2016), 1173–1179.